$EMMA
Emmaus Life Sciences, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023011328 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $6.753M $5.930M $18.39M
YoY Change 108.81% 96.36% -10.77%
Cost Of Revenue $429.0K $645.0K $2.588M
YoY Change -57.4% -67.77% -21.86%
Gross Profit $6.324M $5.285M $15.80M
YoY Change 183.97% 418.65% -8.65%
Gross Profit Margin 93.65% 89.12% 85.93%
Selling, General & Admin $7.200M $6.174M $20.66M
YoY Change 49.1% 25.85% 6.97%
% of Gross Profit 113.85% 116.82% 130.76%
Research & Development $289.0K $529.0K $1.725M
YoY Change -37.98% -50.93% -58.03%
% of Gross Profit 4.57% 10.01% 10.92%
Depreciation & Amortization $9.000K $13.00K $53.00K
YoY Change -18.18% -13.33% -10.17%
% of Gross Profit 0.14% 0.25% 0.34%
Operating Expenses $7.489M $6.703M $22.39M
YoY Change 41.44% 12.02% 444.72%
Operating Profit -$1.165M -$1.418M -$6.586M
YoY Change -62.03% -71.44% 7.47%
Interest Expense $1.502M $1.564M $5.013M
YoY Change 103.8% -153.47% 61.66%
% of Operating Profit
Other Income/Expense, Net $160.0K $150.0K $680.0K
YoY Change -27.93% -20.21% -10.64%
Pretax Income -$3.478M $216.0K -$10.57M
YoY Change 111.43% -103.13% -33.64%
Income Tax $49.00K $16.00K $60.00K
% Of Pretax Income 7.41%
Net Earnings -$3.500M $200.0K -$10.60M
YoY Change 126.98% -102.91% -33.33%
Net Earnings / Revenue -51.83% 3.37% -57.64%
Basic Earnings Per Share -$0.07 -$0.21
Diluted Earnings Per Share -$0.07 $0.00 -$0.21
COMMON SHARES
Basic Shares Outstanding 50.93M 49.56M 49.44M
Diluted Shares Outstanding 50.71M 49.44M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.774M $2.021M $2.021M
YoY Change 118.2% -11.32% -11.32%
Cash & Equivalents $1.774M $2.021M
Short-Term Investments
Other Short-Term Assets $401.0K $449.0K $1.514M
YoY Change 5.8% 13.96% 9.71%
Inventory $2.216M $2.379M $2.379M
Prepaid Expenses $419.0K $467.0K
Receivables $2.204M $375.0K $375.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.418M $6.289M $6.289M
YoY Change 15.04% -30.82% -30.82%
LONG-TERM ASSETS
Property, Plant & Equipment $72.00K $75.00K $2.874M
YoY Change -47.83% -48.98% -20.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.11M $18.83M $38.80M
YoY Change -53.73% 6.88% -11.25%
Other Assets $277.0K $263.0K $263.0K
YoY Change -6.73% -10.85% -10.85%
Total Long-Term Assets $41.53M $41.94M $41.94M
YoY Change -7.81% -11.98% -11.98%
TOTAL ASSETS
Total Short-Term Assets $7.418M $6.289M $6.289M
Total Long-Term Assets $41.53M $41.94M $41.94M
Total Assets $48.95M $48.23M $48.23M
YoY Change -4.95% -15.0% -15.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.733M $3.785M $3.785M
YoY Change 64.74% 39.21% 46.54%
Accrued Expenses $6.718M $7.239M $10.47M
YoY Change 10.4% 24.81% 42.49%
Deferred Revenue
YoY Change
Short-Term Debt $5.641M $5.615M $5.615M
YoY Change -26.39% -35.51% -35.51%
Long-Term Debt Due $23.01M $21.47M $21.47M
YoY Change 79.01% 70.97% 70.97%
Total Short-Term Liabilities $57.86M $54.32M $54.32M
YoY Change 67.45% 46.42% 46.42%
LONG-TERM LIABILITIES
Long-Term Debt $4.426M $3.726M $3.726M
YoY Change -4.82% -19.87% -19.87%
Other Long-Term Liabilities $20.26M $21.71M $24.27M
YoY Change -35.71% -34.54% -33.39%
Total Long-Term Liabilities $20.26M $21.71M $27.99M
YoY Change -35.71% -34.54% -31.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.86M $54.32M $54.32M
Total Long-Term Liabilities $20.26M $21.71M $27.99M
Total Liabilities $84.90M $82.32M $82.32M
YoY Change 15.05% 5.28% 5.28%
SHAREHOLDERS EQUITY
Retained Earnings -$255.9M -$252.3M
YoY Change 4.59%
Common Stock $222.9M $220.9M
YoY Change 0.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$35.95M -$34.09M -$34.09M
YoY Change
Total Liabilities & Shareholders Equity $48.95M $48.23M $48.23M
YoY Change -4.95% -15.0% -15.0%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$3.500M $200.0K -$10.60M
YoY Change 126.98% -102.91% -33.33%
Depreciation, Depletion And Amortization $9.000K $13.00K $53.00K
YoY Change -18.18% -13.33% -10.17%
Cash From Operating Activities -$1.292M $1.677M -$5.073M
YoY Change -72.7% 93.87% 304.55%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $8.000K $26.00K
YoY Change 200.0% -112.9% -64.38%
Acquisitions
YoY Change
Other Investing Activities -$1.085M -$1.054M -$2.361M
YoY Change -188.28% -0.85% -62.55%
Cash From Investing Activities -$1.091M -$1.062M -$2.387M
YoY Change -188.92% -5.6% -62.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.141M 170.0K 7.233M
YoY Change 4.13% -15.0% -2.4%
NET CHANGE
Cash From Operating Activities -1.292M 1.677M -5.073M
Cash From Investing Activities -1.091M -1.062M -2.387M
Cash From Financing Activities 2.141M 170.0K 7.233M
Net Change In Cash -247.0K 785.0K -258.0K
YoY Change -83.15% -1408.33% 24.04%
FREE CASH FLOW
Cash From Operating Activities -$1.292M $1.677M -$5.073M
Capital Expenditures $6.000K $8.000K $26.00K
Free Cash Flow -$1.298M $1.669M -$5.099M
YoY Change -72.59% 80.04% 284.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
http://www.emmausmedical.com/20221231#GainLossOnInvestmentInConvertibleBond
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-255000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Other Comprehensive Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000822370
CY2021 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Other Comprehensive Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-35527
CY2022 dei Entity Registrant Name
EntityRegistrantName
Emmaus Life Sciences, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0419387
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
21250 Hawthorne Boulevard
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Torrance
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90503
CY2022 dei City Area Code
CityAreaCode
310
CY2022 dei Local Phone Number
LocalPhoneNumber
214‑0065
CY2022 dei Security12g Title
Security12gTitle
Common stock, par value $0.001 per share
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
15596954
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50934852
CY2022 dei Auditor Firm
AuditorFirmId
23
CY2022 dei Auditor Name
AuditorName
BAKER TILLY US, LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2021000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2279000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
375000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1040000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4392000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1380000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6289000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
9091000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
18828000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
17616000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2799000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3485000
CY2022Q4 emma Investment In Convertible Bond
InvestmentInConvertibleBond
19971000
CY2021Q4 emma Investment In Convertible Bond
InvestmentInConvertibleBond
26100000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
295000
CY2022Q4 us-gaap Assets
Assets
48225000
CY2021Q4 us-gaap Assets
Assets
56734000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9189000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
703000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
740000
CY2022Q4 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
3248000
CY2021Q4 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
7507000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4404000
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
400000
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
70000
CY2021Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
1503000
CY2022Q4 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
6814000
CY2021Q4 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
2399000
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2367000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
800000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14655000
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
10158000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54323000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37100000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2553000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3261000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33173000
CY2022Q4 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
380000
CY2021Q4 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
1500000
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3346000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3150000
CY2022Q4 us-gaap Liabilities
Liabilities
82316000
CY2021Q4 us-gaap Liabilities
Liabilities
78184000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10565000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15921000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49583501
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49583501
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49311864
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49311864
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
220815000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
220022000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2619000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252337000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241266000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-21450000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48225000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56734000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18390000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20610000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
2588000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
3312000
CY2022 us-gaap Gross Profit
GrossProfit
15802000
CY2021 us-gaap Gross Profit
GrossProfit
17298000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1725000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4110000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7493000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5878000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13170000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13438000
CY2022 us-gaap Operating Expenses
OperatingExpenses
22388000
CY2021 us-gaap Operating Expenses
OperatingExpenses
23426000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6586000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-6128000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-501000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-365000
CY2022 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1304000
CY2021 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
-432000
CY2022 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
4259000
CY2021 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-1906000
CY2022 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-133000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1913000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2733000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2662000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2017000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
680000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
761000
CY2022 us-gaap Interest Expense
InterestExpense
5013000
CY2021 us-gaap Interest Expense
InterestExpense
3101000
CY2022 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-3979000
CY2021 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-9793000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1913000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2733000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-501000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-365000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2022 emma Gain Loss On Sale Of Loss On Leased Assets
GainLossOnSaleOfLossOnLeasedAssets
-22000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10625000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15946000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3084000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1766000
CY2022 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
713000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
367000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2364000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1399000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12989000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17345000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49439867
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49439867
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49253156
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49253156
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-5158000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
500000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
553000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1766000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
367000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15946000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-21450000
CY2022 emma Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity
213000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
119000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3084000
CY2022 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
713000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10625000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2022 us-gaap Profit Loss
ProfitLoss
-10625000
CY2021 us-gaap Profit Loss
ProfitLoss
-15946000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59000
CY2022 emma Inventory Reserve
InventoryReserve
-1565000
CY2021 emma Inventory Reserve
InventoryReserve
-2221000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1815000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1810000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2773000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2004000
CY2022 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-133000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
16000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
553000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
119000
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
500000
CY2022 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1304000
CY2021 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
-432000
CY2022 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
4259000
CY2021 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-1906000
CY2022 emma Gain Loss On Embedded Derivative Note Payable From Related Party
GainLossOnEmbeddedDerivativeNotePayableFromRelatedParty
6000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-607000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
845000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-434000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-462000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-93000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-591000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-566000
CY2022 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
25000
CY2021 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
-30000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3678000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2060000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2777000
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
707000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-317000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-903000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5073000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1254000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2919000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000
CY2022 emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-5280000
CY2021 emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-6304000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2387000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6377000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
6468000
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
3900000
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1700000
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14490000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1809000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
179000
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
976000
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1400000
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
350000
CY2021 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
7200000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7233000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7411000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-31000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-258000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-208000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2279000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2487000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2021000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2279000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1335000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
945000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
21000
CY2022 emma Debt Discount Due To Embedded Derivative
DebtDiscountDueToEmbeddedDerivative
68000
CY2021 emma Debt Discount Due To Embedded Derivative
DebtDiscountDueToEmbeddedDerivative
5555000
CY2022 emma Debt Discount Due To Deferred Financing Cost
DebtDiscountDueToDeferredFinancingCost
328000
CY2022 emma Debt Discount Due To Warrants
DebtDiscountDueToWarrants
84000
CY2022 emma Note Payable Extinguished Through Issuance Of Related Party Note Payable
NotePayableExtinguishedThroughIssuanceOfRelatedPartyNotePayable
1669000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTE 1—DESCRIPTION OF BUSINESS</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—On July 17, 2019 Emmaus Life Sciences, Inc. (formerly, “MYnd Analytics, Inc.” and herein the “Company” or “Emmaus”) completed its merger transaction (the “Merger”) with EMI Holding, Inc., formerly known as Emmaus Life Sciences, Inc. (“EMI Holding”). In the Merger, a wholly owned subsidiary of the Company merged into EMI Holding, with EMI Holding surviving the Merger as a wholly owned subsidiary. Immediately after completion of the Merger, the Company changed its name to “Emmaus Life Sciences, Inc.”</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Merger was treated as a reverse recapitalization under the acquisition method of accounting in accordance with accounting principles generally accepted in the U.S. (“GAAP”) For accounting purposes, EMI Holding was considered to have acquired the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with and prior to the Merger, the Company contributed and transferred to Telemynd, Inc. (“Telemynd”), a newly formed, subsidiary of the Company, all or substantially all of the Company’s historical business, assets and liabilities and the Company’s board of directors declared a stock dividend of share of the Telemynd common stock held by the Company for each outstanding share of Company common stock after giving effect to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1ff01631-9e40-44c4-ab2c-e43e14ed048a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-6</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock of the Company’s outstanding shares of common stock. The dividend, together with the contribution and transfer of the Company’s historical business, assets, and liabilities described above, is referred to as the “spin-off.”</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the spin-off and the Merger, the Company’s ongoing business became EMI Holding’s business, which is that of a commercial-stage biopharmaceutical company focused on the development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">References herein to the “Company” or “Emmaus” means Emmaus Life Sciences, Inc. and its direct and direct subsidiaries.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of Business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—The Company is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of innovative treatments and therapies, primarily for rare and orphan diseases. The Company’s lead product Endari® (prescription grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older. Endari® has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission, which designations generally afford marketing exclusivity for Endari® for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period in the U.S. and for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period in the European Union, respectively, following marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Endari® is marketed and sold by the internal commercial sales team. Endari® is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari® for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari® is also reimbursable by many commercial payors. The Company has agreements in place with the nation’s leading distributors, as well as physician group purchasing organizations and pharmacy benefits managers, making Endari® available at selected retail and specialty pharmacies nationwide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10600000
CY2022Q4 emma Working Capital Deficit
WorkingCapitalDeficit
48000000.0
CY2021Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5153000
CY2022 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
6945000
CY2022 emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
-499000
CY2022 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
7106000
CY2022Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5491000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include those relating to revenue recognition on product sales, the estimated useful lives of equipment, impairment of assets, the variables used to calculate the valuation of conversion features, stock options and warrants, and estimated accruals on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions. To the extent there are material differences between these estimates and actual results, the Company’s financial statements will be affected.</span></p>
CY2021 emma Number Of Vendors
NumberOfVendors
1
CY2022 emma Number Of Vendors
NumberOfVendors
1
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
5000000.0
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3400000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
7144000
CY2021 emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
-92000
CY2021 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
4808000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
52338872
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
23310698
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18390000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20610000
CY2020Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
2726000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1393000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1439000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
513000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
115000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5428000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6228000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4955000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3390000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4392000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
598000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
660000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
467000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
326000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
394000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1380000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
505000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
541000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
430000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
394000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147000
CY2022 us-gaap Depreciation
Depreciation
39000
CY2021 us-gaap Depreciation
Depreciation
46000
CY2020Q3 us-gaap Debt Instrument Call Date Earliest
DebtInstrumentCallDateEarliest
2020-09-28
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-126000
CY2022Q1 us-gaap Other Income
OtherIncome
41000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
26100000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
27866000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
-2919000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-126000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-3084000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-1766000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19971000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
26100000
CY2018Q4 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
32000
CY2018Q4 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
13600000
CY2018Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2028-09-30
CY2018Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.01
CY2022Q4 emma Unsecured Long Term Debt Additional Borrowings
UnsecuredLongTermDebtAdditionalBorrowings
5300000
CY2021Q4 emma Unsecured Long Term Debt Additional Borrowings
UnsecuredLongTermDebtAdditionalBorrowings
6300000
CY2022Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
25000000.0
CY2021Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
22600000
CY2022Q4 emma Cro Expenses
CROExpenses
361000
CY2021Q4 emma Cro Expenses
CROExpenses
534000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
626000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
477000
CY2022Q4 emma Accrued Selling Expenses
AccruedSellingExpenses
1363000
CY2021Q4 emma Accrued Selling Expenses
AccruedSellingExpenses
932000
CY2022Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
650000
CY2021Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
378000
CY2022Q4 emma Accruednonemployeeboardmembercompensation
Accruednonemployeeboardmembercompensation
484000
CY2021Q4 emma Accruednonemployeeboardmembercompensation
Accruednonemployeeboardmembercompensation
136000
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
301000
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
262000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3785000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2719000
CY2022Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
144000
CY2021Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
91000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2381000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
579000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1263000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1097000
CY2022Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
5536000
CY2021Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
4371000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
440000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
332000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5800000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9189000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4404000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33173000
CY2022Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
30418000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
2918000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27562000
CY2022 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
41644749
CY2021Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
22339000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
4332000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18007000
CY2021 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
10173099
CY2022Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.08
CY2021Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.06
CY2022Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.20
CY2021Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.15
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
11837000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
11393000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6149000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
26514000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
383000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3521000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
30418000
CY2022Q3 emma Debt Instrument Principle Payments
DebtInstrumentPrinciplePayments
1600000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
32000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
84000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y1M6D
emma Adjustment Of Warrants Change In Fair Value Increase Additional Paid In Capital And Accumulated Loss
AdjustmentOfWarrantsChangeInFairValueIncreaseAdditionalPaidInCapitalAndAccumulatedLoss
446000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
30000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
25000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
30000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17978000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17019000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5955000
CY2022Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
37000
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
36000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
380000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
292000
CY2022Q4 emma Deferred Tax Assets Unearned Revenue
DeferredTaxAssetsUnearnedRevenue
2472000
CY2021Q4 emma Deferred Tax Assets Unearned Revenue
DeferredTaxAssetsUnearnedRevenue
2393000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
442000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
167000
CY2022Q4 emma Deferred Tax Assets Unrealized Gain Loss On Foreign Exchange Translation And Other
DeferredTaxAssetsUnrealizedGainLossOnForeignExchangeTranslationAndOther
789000
CY2021Q4 emma Deferred Tax Assets Unrealized Gain Loss On Foreign Exchange Translation And Other
DeferredTaxAssetsUnrealizedGainLossOnForeignExchangeTranslationAndOther
133000
CY2022Q4 emma Deferred Tax Assets Section One Seventy Four Expenditures
DeferredTaxAssetsSectionOneSeventyFourExpenditures
292000
CY2022Q4 emma Deferred Tax Assets Unrealized Gain Loss On Long Term Investment
DeferredTaxAssetsUnrealizedGainLossOnLongTermInvestment
33000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4130000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3188000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44539000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40576000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44112000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40147000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
427000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
429000
CY2022Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
426000
CY2021Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
427000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
427000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
429000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4000000.0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2700000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
11800000
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
11400000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2242000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3359000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-453000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-275000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3964000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2722000
CY2022 emma Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-384000
CY2021 emma Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
1337000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
450000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
902000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-375000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
502000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-31000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1049000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1063000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1092000
CY2022Q4 emma Lessee Operating Leases Liability Payment Due Year Four And Thereafter
LesseeOperatingLeasesLiabilityPaymentDueYearFourAndThereafter
836000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4040000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
784000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3256000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2800000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3300000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4000000.0
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.129
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
74000
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
91000

Files In Submission

Name View Source Status
0000950170-23-011328-index-headers.html Edgar Link pending
0000950170-23-011328-index.html Edgar Link pending
0000950170-23-011328.txt Edgar Link pending
0000950170-23-011328-xbrl.zip Edgar Link pending
emma-20221231.htm Edgar Link pending
emma-20221231.xsd Edgar Link pending
emma-ex10_42.htm Edgar Link pending
emma-ex10_43.htm Edgar Link pending
emma-ex19_1.htm Edgar Link pending
emma-ex23_1.htm Edgar Link pending
emma-ex31_1.htm Edgar Link pending
emma-ex31_2.htm Edgar Link pending
emma-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img48252078_0.jpg Edgar Link pending
img48252078_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
emma-20221231_lab.xml Edgar Link unprocessable
emma-20221231_pre.xml Edgar Link unprocessable
emma-20221231_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
emma-20221231_cal.xml Edgar Link unprocessable
emma-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable